Impact of Smoking in Cutaneous Lupus Erythematosus

Piette, Evan W.; Foering, Kristen; Chang, Aileen Y.; Okawa, Joyce; Have, Thomas R. Ten; Feng, Rui; Werth, Victoria P.

doi:10.1001/archdermatol.2011.342

Cited by 94 publications

(62 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three of the 45 patients in this group were current smokers. Comparing our data with previously published lupus data that found that 50 of 149 patients with active CLE were current smokers, 10 the number of current smokers is significantly less in DM than CLE (P=0.0002).…”

Section: Resultssupporting

confidence: 81%

Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life

et al. 2014

View full text Add to dashboard Cite

Background Cutaneous dermatomyositis (DM) disease activity is associated with a decreased quality of life. Objectives This prospective study assessed if an improvement in quality of life, as measured by the Skindex-29 and patient-reported itch and pain on a 10-point visual analog scale (VAS), correlated with an improvement in cutaneous DM disease activity. Methods Patients with a completed cutaneous DM disease area and severity index (CDASI) at two visits separated by at least two months were classified into responder (n=15) and non-responder (n=30) groups according to the point change in the CDASI activity scores between visits. Responders had at least a four-point improvement in CDASI activity, indicating clinically relevant improvement. Results The change from baseline to the follow-up visit of the Skindex-29 subscale scores for the responders versus the non-responders were significantly different: emotions P=0.0047, functioning P=0.0026, and symptoms P<0.0001. The change in VAS score between responders and non-responders was also significant for itch (P=0.0135) and pain (P=0.0367). The was no significant difference between the groups in terms of disease subtype, sex, race, age, treatment for DM, smoking history, or history of malignancy within five years of DM diagnosis. Conclusions This is the first study to demonstrate that the quality of life of patients with DM improved as their cutaneous disease activity decreased.

show abstract

Section: Resultssupporting

confidence: 81%

Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life

et al. 2014

View full text Add to dashboard Cite

show abstract

“…However, we chose to suspend the treatment due to improvement in the vision of the patient and the report of the ophthalmologist. Moreover, we must not forget that smoking has been linked to a decrease in the efficacy of antimalarial drugs in several studies [20,21], so it is important to advise patients about the need to give up smoking. Considering our case series, we think that a longer duration of antimalarial therapy at a higher dose may be necessary due to the relapse of 5 patients, 2 of whom relapsed after 5 and 6 months of treatment (patients 5 and 7).…”

Section: Discussionmentioning

confidence: 99%

Antimalarial Drugs for the Treatment of Oral Erosive Lichen Planus

Rivas-Tolosa

Requena

Llombart³

et al. 2015

Dermatology

View full text Add to dashboard Cite

Background: Treatment of oral erosive lichen planus is considered a therapeutic challenge. Various systemic and topical agents aimed at controlling the symptoms, rather than curing the lesions, have been used with varying results. Objective: To evaluate the response to treatment with antimalarial drugs in patients with oral erosive lichen planus. Methods: Eight patients diagnosed with oral erosive lichen planus were treated with antimalarial agents. The first clinical evaluation was made after a month of treatment and then every 2-3 months. Baseline ophthalmologic examinations were performed, and laboratory values were monitored before and during treatment. Results: All studied patients who had previously been resistant to other treatments responded favorably. Pain relief and reduced erythema and erosions were observed after of a mean of 2.4 months. Conclusion: Antimalarials may be useful for the treatment of oral erosive lichen planus. They are easily administered and affordable, with few adverse effects.

show abstract

“…Quinacrine users (n=314) were more likely to have smoking history (current=20.6%, past=28.8%, never=50%) than non-users (n=222, current=16.2%, past=19.4%, never=64.4%), χ 2 (2, N =536) =10.79, p=0.0045, likely representing treatment escalations required in smokers (Table 1). 2 …”

Section: To the Editormentioning

confidence: 99%

The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis

Mittal

Werth

2017

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Impact of Smoking in Cutaneous Lupus Erythematosus

Abstract: To investigate cigarette smoking in cutaneous lupus erythematosus (CLE).

Cited by 94 publications

References 21 publications

Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life

Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life

Antimalarial Drugs for the Treatment of Oral Erosive Lichen Planus

The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis

Contact Info

Product

Resources

About